Advertisement
Advertisement
May 15, 2017
FDA Approves Phase 1 Trial of Alucent Medical's Natural Vascular Scaffold Therapy
May 16, 2017—Alucent Medical, Inc. announced that it has received US Food and Drug Administration (FDA) approval to begin phase 1 human clinical studies of the company's Natural Vascular Scaffolding (NVS), which is a novel combination drug/device therapy for the treatment of peripheral vascular disease (PVD). NVS is designed to build natural and durable scaffolding to keep the vessel open, possibly replacing the need for an implanted stent.
The company-sponsored phase 1 NVS Therapy trial will commence in Summer 2017 at three locations in the United States. The trial will be led by Principal Investigator Gary Ansel, MD, who is System Medical Chief, Vascular Program, at OhioHealth in Columbus, Ohio.
Alucent Medical, which is headquartered in Salt Lake City, Utah, is a new company formed to develop and market the novel NVS therapy. The company is owned by the research and development arm of Avera Health, which is based in Sioux Falls, South Dakota. NVS was initially developed by a team of Avera scientists led by founder Ron Utecht, PhD.
Advertisement
Advertisement
